TITLE

U.S. BIODEFENSE/UCL BIOMEDICA GET OPTION TO LICENSE PATENT

PUB. DATE
April 2005
SOURCE
Worldwide Biotech;Apr2005, Vol. 17 Issue 4, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the agreement between U.S. BioDefense Inc. and UCL BioMedica for the license patents of several liver disease treatments. Terms of the agreement; Remarks of U.S. BioDefense CEO David Chin regarding the agreement; Information on the operations of U.S. BioDefense Inc.
ACCESSION #
16581053

 

Related Articles

  • Ovarian and Cervical Cancers Update.  // PharmaWatch: Cancer;Nov2005, Vol. 4 Issue 11, p6 

    The article presents information about various studies related to ovarian and cervical cancers. A phase II study of Avastin in advanced ovarian cancer has been suspended by Genentech Inc. after an increased rate of gastrointestinal bleeding was found in the patients. Cervical cancer vaccine...

  • Coming Monday in BioWorld Insight.  // BioWorld Today;3/22/2013, Vol. 24 Issue 55, p8 

    The article presents an overview of topics that will be featured in the March 25, 2013 issue of "BioWorld Insight," including early warning signs to combat emerging diseases, a licensing agreement entered by Galena Biopharma Inc. and an online course about epidemics.

  • Deals roundup.  // Medical Device Daily;5/26/2010, Vol. 14 Issue 101, p5 

    This article reports that Valocor Therapeutics has acquired and licensed certain dermatology therapeutic programs from QLT.

  • Agreements/contracts.  // Medical Device Daily;4/18/2012, Vol. 16 Issue 75, p7 

    The article reports on the exclusive worldwide license granted by Dyax to Eclipse Therapeutics for the development and commercialization of preclinical fully-human antibodies discovered through the phage display technology of Dyax for use in oncology indications.

  • Jilted PharmAthene Prevails.  // BioWorld Today;5/29/2013, Vol. 24 Issue 102, p8 

    The article reports on the decision of the Delaware Supreme Court to upheld a lower court ruling that found SIGA Therapeutics Inc. breached its contractual obligation to negotiate a licensing agreement in good faith with PharmAthene Inc.

  • Agreements/contracts.  // Medical Device Daily;10/15/2010, Vol. 14 Issue 201, p3 

    The article reports on a partnership and license agreement between San Diego, California-based Fate Therapeutics and Becton, Dickson and Co. (BD) for the manufacturing and commercialization of induced pluripotent stem cell (iPSC) instruments and technologies for drug development.

  • Pluristem, United Therapeutics Sign $62M Licensing Deal.  // Bioworld Week;6/27/2011, Vol. 19 Issue 26, p3 

    The article reports on the licensing deal signed by Pluristem Ltd. with United Therapeutics Corp. for its PLacental eXpanded (PLX) cell pipeline in the U.S.

  • Potter type III cystic disease and pancreatic malignancies. Otani, Taiichi; Makuuchi, Masatoshi // Journal of Gastroenterology;2001, Vol. 36 Issue 6, p438 

    Editorial. Presents information on adult polycystic liver disease (APLD). Diseases which are usually complained by patients with APLD; Treatment methods for the disease; Proposed classifications of cystic disease.

  • hepatotherapy.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1063 

    An encyclopedia entry for "hepatotherapy," which refers to the treatment of liver diseases, is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics